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Abstract TGFβ1 is the most pleiotropic of all known
cytokines and thus, to avoid uncontrolled TGFβ-
activated processes, its activity is tightly regulated.
Studies in fibrosis have led to the discovery that αv
integrins are the major regulators of the local activation
of latent TGFβ in our tissues. Since all cells can express
one or more types of αv integrins, this raises the possi-
bility that, in the complex milieu of a developing cancer,
multiple cell types including both cancer cells and stromal
cells activate TGFβ. In normal tissues, TGFβ1 is a tu-
mour suppressor through its ability to suppress epithelial
cell division, whereas in cancer, in which tumour cells
develop genetic escape mechanisms to become resistant
to TGFβ growth suppression, TGFβ signalling creates a
tumour-permissive environment by activating fibroblast-
to-myofibroblast transition, by promoting angiogenesis,
by suppressing immune cell populations and by promot-
ing the secretion of both matrix proteins and proteases. In
addition, TGFβ drives epithelial-to-mesenchymal transi-
tion (EMT) increasing the potential for metastasis. Since
αv integrins activate TGFβ, they almost certainly drive
TGFβ-dependent cancer progression. In this review, we
discuss the data that are helping to develop this hypothe-
sis and describe the evidence that αv integrins regulate
the TGFβ promotion of cancer.
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Introduction
Transforming growth factor β1 (TGFβ1) is a pleiotropic cy-
tokine that can function as both tumour suppressor and tumour
promoter (for reviews, see Inman 2011; Yang and Moses
2008; Roberts and Wakefield 2003). TGFβ1-dependent tu-
mour suppression is attributable mostly to the direct effects
of the inhibition of epithelial cell division by the activation of
cyclin-dependent kinase inhibitors (p21, p15 Ink4b). Once
tumour cells develop mutations that render them refractile to
the growth-suppressive effects of TGFβ1, then the cytokine
can become tumour-promoting by acting directly on the tu-
mour cells to drive an invasive programme but also indirectly
by promoting a tumour-permissive microenvironment (Inman
2011).
In the last 20 years, it has become clear that the αv
family of RGD-binding integrins are major regulators of
TGFβ1-dependent processes in both normal and patho-
logical processes (for reviews, see Wipff and Hinz 2008;
Margadant and Sonnenberg 2010; Sheppard 2015). Some
of these same integrins have also been strongly implicated
in the promotion of the growth and spread of many dif-
ferent types of cancer. Therefore, integrins that are able to
activate TGFβ1 in vivo are probably also likely to mod-
ulate tumour progression indirectly via the local produc-
tion of active TGFβ1. Strong data also describe the way
that TGFβ1 regulates the tumour microenvironment
(TME) to regulate cancer progression. In this review, we
will combine those data and extrapolate from a combina-
tion of in vitro and clinical observations to infer the likely
roles of integrin-dependent TGFβ1 regulation of the
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tumour stroma. First, we will review briefly the integrin-
dependent activation of latent-TGFβ1 and those integrins
that are candidates for the activation of TGFβ1 in cancer.
TGFβ is deposited in extracellular matrix
as an inactive latent complex
The TGFβ family of cytokines and receptors includes
activins, bone morphogenetic proteins and the TGFβ cyto-
kines. In this review, we will concentrate on TGFβ1 but direct
readers to a recent excellent review of other members of the
family (Wakefield and Hill 2013). Three isoforms of TGFβ
(TGFβ1, TGFβ2 and TGFβ3) are widely expressed in tissues
but have different functions. Knockout of the TGFβ1 gene in
mice (tgfb1) results in the infiltration of tissues with mononu-
clear cells eventually killing the animal within weeks of birth
(Shull et al. 1992; Kulkarni et al. 1993), whereas the knockout
of TGFβ2 (Sanford et al. 1997) or TGFβ3 (Kaartinen et al.
1995) causes developmental defects. All three isoforms of
TGFβ bind to the same cell surface receptor TGFBRII, which
exists as a dimer, a constitutively active serine-threonine ki-
nase that, upon binding a ligand, dimerises with and phos-
phorylates a dimer of TGFBRI (also known as ALK5)
forming a quaternary complex (Kang et al. 2009). This com-
plex recruits and activates via phosphorylation the SMAD2
and SMAD3 transcription factors, which now can bind
SMAD4 promoting their translocation to the nucleus in which
the complex drives the transcription of a wide variety of
genes, including the αv integrins (Levy and Hill 2005;
Margadant and Sonnenberg 2010). TGFβ also activates mul-
tiple SMAD-independent signalling pathways that can pro-
mote tumour progression (Inman 2011).
TGFβ1 is a highly pleiotropic cytokine, which is probably
the reason that its synthesis and activation is so tightly con-
trolled. As described previously (Annes et al. 2004), the
TGFβ1 gene product (TGFB1) is generated as a homo-
dimer that is post-translationally cleaved by Furin-like en-
zymes into a larger pro-peptide, called the latency-associated
peptide (LAP), which associates with the smaller TGFβ cyto-
kine, the last-mentioned remaining non-covalently bound; this
is referred to as the small latent complex (SLC). Two such
processed proteins form a homo-dimer, which become cova-
lently linked to one of four latent TGFβ-binding proteins
(LTBP-1,-2,-3 and -4) within the Golgi prior to being secreted
as a large latent complex (LLC) of LAP-TGFβ-LTBP. The
LLC becomes anchored in the matrix via covalent linkage of
LTBPs to fibrillin-1 (for a review, see Robertson et al. 2015).
The concentration of TGFβ1 embedded in the extracellular
matrix of normal organs has been estimated to be far in excess
of that required to promote most TGFβ1-mediated processes
(Sheppard 2015). However, while embedded within the LLC,
the TGFβ1 remains inert. Thus, TGFβ1-dependent processes
are controlled locally in the tissues by the regulation of the
activation of latent-TGFβ1, which is, effectively, the exposure
or release of the TGFβ1 cytokine to access by TGFβ1 recep-
tors. This is important as uncontrolled TGFβ activity can lead
to chronic fibrosis (Margadant and Sonnenberg 2010), which
can be a significant risk factor for the development of some
cancers (Hubbard et al. 2000; Bataller and Brenner 2005).
Integrin activation of latent TGFβ in vivo
Munger and colleagues reported that the RGD-binding
integrin αvβ6 activates latent TGFβ1 by binding to the
RGD motif of LAPβ1 and exerting an actin-dependent phys-
ical deformation of the LLC, exposing the TGFβ cytokine to
TGFβ receptors on adjacent cells (Munger et al. 1999). Of
note, αvβ6 also binds TGFβ3 in a similar fashion. The pro-
cess, which is protease-independent, has been subsequently
shown to require fibronectin-anchored LTBP1 (Annes et al.
2004; Dallas et al. 2005). Biologically, the epithelial-specific
αvβ6 is required to promote lung fibrosis in response to
bleomycin (Munger et al. 1999) and, in separate studies, kid-
ney fibrosis in response to deficiency in the collagen subunit
Col4A3 (Hahm et al. 2007) and in both cases, antibodies to
αvβ6 suppress fibrosis. Wipff et al. (2007) reported that
thrombin-activated contraction by myofibroblasts activates
TGFβ1 predominantly via αvβ5 and, less so, via αvβ3 or
an unidentified β1 integrin (Wipff et al. 2007). The process of
activation is also wholly mechanical, since detergent-treated
cells lacking any cell membrane or cytosol can still activate
latent TGFβ1 in response to exogenous ATP; again, αvβ5
blockade reduces this TGFβ1 activation by 66 %, twice as
much as a blockade of αvβ3 or β1 integrins. Henderson et al.
(2013) reported that mice globally deficient for integrin sub-
unit genes, namely itgb3, itgb5 or itgb6 and selectively defi-
cient for itgb8 in haemopoietic cells are not protected from
experimental liver fibrosis induced by carbon tetrachloride
treatment, whereas mice with myofibroblasts deficient in the
αv gene (itgav) are protected (Henderson et al. 2013). Using
anαvβ1-specific peptide inhibitor, Henderson and colleagues
confirmed that αvβ1 can promote liver fibrosis, possibly
identifiying the TGFβ1-activating β1 integrin earlier de-
scribed by Wipff et al. (2007). These data show that
integrin-dependent TGFβ1 activation can vary between tis-
sues and cell types. Henderson and colleagues also concluded
that αvβ1 promotes bleomycin-induced lung fibrosis in mice.
Since the same group has previously reported αvβ6 as being
the driver of bleomycin-induced lung fibrosis (Munger et al.
1999), these results suggest that two or more TGFβ1-
activating integrins can operate simultaneously in a single
tissue to regulate the stromal response. This has implications
for the TGFβ1-dependent modulation of the tumour microen-
vironment in cancer.
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In contrast to other integrins, αvβ8 activates latent-TGFβ1
in a protease-dependent manner by the co-localisation of
membrane-bound protease MT1-MMP/MMP14 (Mu et al.
2002). Thus, αvβ8 binds to LAPβ1 or LAPβ3 and brings
the latent complexes into proximity of the membrane-bound
protease that cleaves the LAP. Integrin αvβ3 might also be
capable of using proteases to activate latent TGFβ in vivo, as
reports exist that αvβ3 can localise activated matrix metallo-
proteinase 2 (MMP2) and MMP9 at the cell surface (Brooks
et al. 1996; Rolli et al. 2003) and these MMPs have been
implicated as activators of TGFβ in vitro (for a discussion,
see Jenkins 2008).
The specific importance of RGD-binding integrins as reg-
ulators of TGFβ activity in vivo has been confirmed by the
creation of mice with LAP but containing the non-integrin
binding motif RGE, instead of RGD. These mice have a phe-
notype that mirrors that of TGFβ1-deficient mice (Yang et al.
2007). However, despite the evidence that all αv integrins
appear to activate latent TGFβ, mice deficient in αvβ3 or
αvβ5 do not exhibit TGFβ1-deficient phenotypes, whereas
mice deficient in αvβ6 exhibit skin and lung inflammation
(Munger et al. 1999), the spontaneous development of several
types of cancers (Ludlow et al. 2005) and emphysema in older
mice (Morris et al. 2003), all phenotypes linked to deficient
local TGFβ1 activity. Similarly, whereas the complete abla-
tion of integrin αvβ8 is a lethal phenotype (Zhu et al. 2002),
loss in dendritic cells results in chronic inflammation and au-
toimmunity, almost certainly attributable to the inability of
dendritic cells to activate TGFβ1 and thereby regulate the
production of TReg cells (Travis et al. 2007). Thus, the appar-
ent ranking in the ability of integrins to activate TGFβ1
in vivo might be linked to their affinity for LAP. The sequence
RGDLXXI, as occurs in LAPβ1 and LAPβ3, forms two bind-
ing sites for αvβ6: the RGD loop and an adjacent helix that
presents a hydrophobic leucine/isoleucine-binding site permit-
ting high affinity binding (DiCara et al. 2007) and probably
also explaining the high affinity of αvβ8 for LAPβ1 (Mu
et al. 2002). In contrast, no reports are available for a second
binding site in LAPβ1 for other αv integrins. However, if the
threshold for activating TGFβ1 was lowered, then the weaker
binding αv integrins, namely αvβ5, αvβ3 and αvβ1, might
play a larger role in local TGFβ1 activation. As discussed
below, this is likely to occur.
As mentioned above, researchers at the Hinz laboratory
reported that myofibroblasts express several αv integrins
that can activate TGFβ1, including αvβ3, αvβ5 and an
unidentified β1 integrin. They found that the integrin ac-
tivation of TGFβ1 does not occur on soft pliable sub-
strates but also established that the stretching of adherent
myofibroblasts is sufficient to increase their ability to ac-
tivate latent TGFβ1 (Wipff et al. 2007). More recently,
Klingberg et al. (2014) showed that, when myofibroblasts
remodel the extracellular matrix through their contractile
activity, they also organise LTBP1 into fibrillar fibronec-
tin deposits, whereas normal fibroblasts are less able to
achieve this (Klingberg et al. 2014). Furthermore,
myofibroblasts can activate twice as much TGFβ1 on
the myofibroblast-organised matrix than the fibroblast-
organised matrix, suggesting that placing the matrix under
tension primes the latent TGFβ1 for activation. This has
been established by using a strain machine that stretches
cell-depleted extracellular matrices before cells are added.
Myofibroblasts activate TGFβ1 more efficiently on
stretched matrices and this correlates with the stretching
of the LTBP1-Fn deposits, as observed by fluorescence
microscopy. Indeed, a fraction of TGFβ1 is activated in-
dependently of integrins if the matrix is sufficiently
stretched.
Thus, non-proteolytic TGFβ1 activation by αv integrins is
regulated at many levels: (1) sufficient amounts of an appropri-
ate LAP-binding integrin must be present, (2) the integrin must
be in the ligand-binding activated state (Wipff et al. 2007), (3)
the cytoplasmic tail must be linked directly to the actomyosin
cytoskeleton, (4) the extracellular domain is bound to LAPβ1
or LAPβ3 of the LLC, (5) the LLC must be anchored to a
strain-resistant matrix in order to permit actin-dependent
stretching of the complex to reveal the TGFβ. Finally, if the
responding cell is adjacent to these activating events, this max-
imises the controlled local activation (Munger et al. 1999).
Such tight control allows the exquisite regulation of TGFβ1
in our tissues. However, once the process has started, the acti-
vation of latent TGFβ1 might be rapidly amplified through
integrin-dependent positive feedback loops; this is likely to
happen in both fibrosis and cancer. Thus, as described in
Fig. 1, the initial activation of TGFβ1 can increase the expres-
sion of more TGFβ-activating integrin subunits on both epithe-
lial cells and local fibroblasts through SMAD-dependent sig-
nalling (Margadant and Sonnenberg 2010). Moreover, the acti-
vated TGFβ1 activates local fibroblasts to become
myofibroblasts (discussed below), which develop contractile
abilities and contract the extracellular matrix. The contracted
matrix stretches the embedded LLC and lowers the threshold
for activating more latent TGFβ1, potentially allowing
integrins with a lower affinity for LAP (αvβ5, αvβ1, αvβ3)
to activate more TGFβ1. The additional TGFβ1 generated fur-
ther amplifies the process potentially resulting in a cycle of
TGFβ1 activation-fibroblast activation-extracellular matrix
stiffening-TGFβ1 activation etc. Thus, cancers can progress
to a point at which the tumour:stroma interaction develops into
an activation loop whereby the upregulated αv integrins, in-
creasedmatrix stiffness and probably proteases released by both
tumour and myofibroblasts result in uncontrolled TGFβ1 acti-
vation. This raises the question as to which point(s) within this
escalation of TGFβ1 activation therapeutic intervention is still
likely to be effective. Logically, the early blockade of a limited
number of αv integrins as shown in fibrosis studies (Munger
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et al. 1999; Hahm et al. 2007) will probably suppress TGFβ1
activation in the tumour microenvironment but, once escalated,
TGFβ1 activationmight occur viamanymechanisms and, thus,
multiple interventions will be needed, which will be therapeu-
tically challenging. Notably, whereas the remaining RGD-
binding integrins (α5β1, α8β1 and αIIbβ3) have not been
reported to activate latent TGFβ1 directly, α5β1 is required
for the αvβ6-dependent activation of latent TGFβ1 (Fontana
et al. 2005) presumably by binding to the fibronectin trapping
the LTBP1.
TGFβ1-driven changes in the tumour
microenvironment can promote cancer progression
Recent reviews have described the role of TGFβ1 in the reg-
ulation of the tumour microenvironment (Pickup et al. 2013;
Lin and Zhao 2015; Guo et al. 2016). In this review, we will
concentrate on the available evidence linking integrin-
dependent TGFβ1 activation to many of these microenviron-
mental changes.
1) Integrin activation of TGFβ drives epithelial-to-
mesenchymal transition
The epithelial-to-mesenchymal transition (EMT) is the pro-
cess by which epithelial cells reduce the expression or func-
tion of the proteins that promote cell-cell and cell-basement-
membrane adhesion and thus transition towards a more motile
and sometimes mesenchymal-like phenotype. This transition
is essential during stages of embryogenesis and wound
healing but also occurs in pathological processes, possibly
for the initiation of metastasis (Mamuya and Duncan 2012).
TGFβ1 induces EMT by generating a transcriptional repres-
sion of the epithelial gene signatures, including cell-cell adhe-
sion molecule E-cadherin but by elevating mesenchymal
genes, such as N-cadherin, αSMA and vimentin in a
SMAD-dependent and -independent manner, in part via acti-
vation of the transcription factors Snail and Slug (Naber et al.
Fig. 1 Cycle of contribution of transforming growth factor β1 (TGFβ1)-activated fibroblasts to extracellular matrix (ECM) composition and stiffness
and further TGFβ1 activation (LTBP latent TGFβ-binding proteins, ITGB6 integrin subunit gene 6, LOX lysyl oxidase, POSTN periostin)
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2013; Medici et al. 2006). Thus, the integrin-dependent acti-
vation of TGFβ1 might be expected to promote EMT, as has
been reported.
Bates and colleagues (2005) reported that high levels of
αvβ6 in colon cancer reduced overall survival from a median
of 16.5 months in the αvβ6-low/negative cancers to 5 months
in the αvβ6 strongly positive cancers. They also suggested a
model of αvβ6-dependent activation of TGFβ1 and subse-
quent EMTas the potential mechanism forαvβ6-driven colon
cancer (Bates et al. 2005).
Workers at the Danen laboratory discovered that the reduc-
tion ofβ1 integrin expression in breast cancer cells suppressed
tumour growth but enhanced metastasis to the lungs. In three-
dimensional (3D) matrices in vitro, similar treatments with
integrin β1 inhibitory antibodies or genetic suppression of
β1 expression resulted in a change from cohesive migration
to single cell migration; this was dependent upon increased
TGFβ1 signalling and was correlated with the loss of E-
cadherin. Suppression of TGFβ1 signalling or increasing E-
cadherin restored cohesive migration in β1-deficient cells and
reduced their metastasis to the lungs (Truong et al. 2014).
These observations were in agreement with earlier studies by
Giampieri et al. (2009) who reported that activation of TGFβ1
signalling in a tumour cell population promoted a single cell
migratory phenotype as opposed to cohesive cell migration in
the absence of TGFβ1 signalling (Giampieri et al. 2009).
These data link αv integrin activation of latent TGFβ1 direct-
ly to the metastatic propensity of cancer (Mamuya and
Duncan 2012).
Sometimes, the upregulation of TGFβ1 signalling by
integrins is indirect. Mori and colleagues showed that αvβ3
enhanced TGFβ1-induced EMT in MCF10A breast cells by
binding directly to fibroblast growth factor 1 (FGF1) andmak-
ing it available for binding to FGFR1 receptors. This
FGF1-αvβ3 engagement and the FGFR1 signalling were nec-
essary for FGF1 to maximise the TGFβ1-dependent EMT
(Mori et al. 2015). TGFβ1 also elevates the expression of
secreted matricellular glycoprotein fibulin-5, which contains
an RGD-motif and is capable of binding α5β1, αvβ3 and
αvβ5 (Yanagisawa et al. 2009). Fibulin-5 is expressed during
development and is only re-expressed in injured tissues and
cells undergoing EMT. Moreover, fibulin-5 stimulates MMP-
2 and -9 expression and activity and promotes mammary ep-
ithelial cell invasion probably through an enhancement of
Twist and reduction in E-cadherin expression. However, the
direct link between fibulin-5 and integrins during EMT needs
to be further established (Lee et al. 2008).
2) Empirical and inferred data linking integrin activa-
tion of TGF to modulation of the tumour stroma
We only recently established the central importance of
the many different αv integrins in the activation of latent
TGFβ and determined which αv integrins are likely to act
when and where (see above). Therefore, relatively few
studies have included integrin-blocking antibodies in their
in vivo investigations in order to empirically determine
which integrin, if any, is responsible for activating
TGFβ1 and therefore is responsible for the TGFβ1-
dependent effects on tumour cell growth and spread and
the tumour microenvironment. In this section, we summa-
rise both empirical data, whereby researchers have direct-
ly examined the role of integrin-dependent TGFβ activity
in tumour progression and inferred data, whereby we can
reasonably assume that integrin-dependent TGFβ1 activa-
tion is at play.
Van Aarsen et al. (2008) showed that Detroit-562 oral
squamous cell carcinoma (SCC) xenografts developed a
strongly positive αvβ6 invasive front and grew into a
stroma rich in TGFβ1. Moreover, the xenografts exhibited
a reticular αSMA pattern in the stroma at the periphery of
the tumour correlating with the expression of αvβ6 and
suggesting a relationship between the two proteins (Van
Aarsen et al. 2008). A similar accumulation of αSMA-
positive myofibroblasts abutting the invasive front of oral
cancer, most of which were αvβ6-positive (Van Aarsen
et al. 2008; Marsh et al. 2011), had been observed previ-
ously (Lewis et al. 2004). Treatment of Detroit-562 xeno-
grafts by systemic αvβ6-blocking antibody 6.3G9 or sol-
uble recombinant TGFBRII-Fc protein suppressed tumour
growth but did not significantly change the expression of
αSMA, CD31-positive blood vessels or collagen deposi-
tion detected by Sirius red staining (Van Aarsen et al.
2008). In contrast, Eberlein and colleagues (2013) report-
ed that the treatment of mice bearing Detroit-562 xeno-
grafts with 264RAD, a human antibody that inhibits
αvβ6, resulted in a dose-dependent reduction in tumour
growth that was mirrored by a dose-dependent reduction
in fibronectin and SMA, two products of TGFβ-activated
fibroblasts, suggesting strongly that αvβ6 was promoting
a myofibroblast-rich microenvironment. Why these simi-
lar studies resulted in different apparent stromal effects
remains unknown. Whether the small amount of αvβ8
blocking activity of the 264RAD antibody had any effect
was not explored.
Moore and colleagues reported thatαvβ6 co-operated with
HER2 to promote HER2-driven invasive breast cancer
(Moore et al. 2014). Treatment of mice with 264RAD sup-
pressed the growth of both HER2-over-expressing BT474 and
MCF7/HER2-18 tumours, an effect enhanced by combination
therapy with the anti-HER2 antibody Trastuzumab. Analysis
of tumours harvested mid-therapy showed that, in both tu-
mour types, 264RAD therapy alone was sufficient to reduce
total- and phospho-SMAD2 in the tumour and to reduce the
number of αSMA-positive and endomucin-positive endothe-
lial cells suggesting a direct link between αvβ6-dependent
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TGFβ1 signalling, the induction of myofibroblasts and the
upregulation of angiogenesis.
Integrin activation of TGFβ1 influences cancer progres-
sion not only on the luminal component of breast tissue.
Myoepithelial cells are the contractile cells adjacent to luminal
breast cells that promote milk secretion from ducts. Allen et al.
(2014) identified de novo expression of αvβ6 on breast
myoepithelial cells as being a key biomarker associated with
an invasive breast phenotype in ductal carcinoma in situ
(DCIS; Allen et al. 2014). Moreover, a relationship existed
between αvβ6-positive myoepithelial cells in DCIS and the
subsequent recurrence of breast cancer. Since only 50 % of
women with DCIS develop life-threatening invasive ductal
carcinoma but still receive surgery and other therapies, this
is an important observation with potential clinical ramifica-
tions. To determine the mechanism, Allen and colleagues
showed that, when αvβ6 was over-expressed on normal
myoepithelial cells, they could activate TGFβ1 to which they
responded by upregulating MMP2 and MMP9. Blockade of
TGFβ or MMPs inhibited the ability of αvβ6-expressing
myoepithelial cells to promote breast cancer invasion.
Analysis of DCIS samples confirmed a strong correlation of
αvβ6 and MMP9 expression in myoepithelial cells. In further
studies, the injection of αvβ6-positive myoepithelial cells to-
gether with MDAMB231 breast carcinoma cells resulted in a
significantly faster growth of tumours compared with normal
myoepithelial cells. Again, the data were consistent with the
αvβ6 activation of TGFβ1 driving tumour cell invasion ex-
cept that, this time, the αvβ6-positive Bmicroenvironmental^
myoepithelial cell promoted the invasive phenoptype.
Marsh and colleagues reported that, compared with the
more indolent types of basal cell carcinoma (BCC), αvβ6
was selectively upregulated on the morphoeic type of
BCC, a tumour that has a distinctly invasive and fibrotic
phenotype (Marsh et al. 2008). As BCC is associated with
the upregulation of Gli 1 and Gli 2 transcription factors,
they were transfected into keratinocytes to generate an
in vitro model of BCC. These cells were able to activate
latent TGFβ1, which activated fibroblasts to become
αSMA-positive myofibroblasts and which, in turn, secret-
ed HGF that acted as a pro-invasive chemoattractant for
the BCC cells. The data were consistent with increased
αvβ6 expression by morphoeic BCC cells being signifi-
cantly responsible for the invasive and fibrotic phenotype
of this disease. Another skin carcinoma study also linked
αvβ6 to the modulation of the TME. Patients lacking
collagen 7 fibrils easily develop skin blisters that further
develop into chronic fibrotic inflammatory lesions on
bony joints and can often develop into invasive and met-
astatic squamous carcinomas (Fine and Hintner 2009).
Martins et al. (2016) developed 3D tumour-mimetic
organotypic gels in vitro combining a squamous cell car-
cinoma (SCC) cell line that had been engineered to lack
collagen 7 gene (Col7A1) with fibroblasts in a collagen-
based gel. Small-hairpin-RNA-treated SCC cells (shCol7
SCC) admixed with skin fibroblasts invaded significantly
more than control cells and upregulated αvβ6 and the
associated matrix exhibited a significant increase in fibro-
nectin. The increased invasion, αvβ6 expression and fi-
bronectin were all suppressed by co-incubation with a
TGFβ1 receptor inhibitor. When the organotypic gels
were implanted under the skin of mice to form tumours,
again the loss of collagen 7 resulted in significant upreg-
ulation of αvβ6 expression specifically at the invasive
front and a significant increase in fibronectin expression
in the associated stroma and cancer. Moreover, increased
phospho-Smad2/3 signalling was present in the stroma of
the Col7-deificient SCC tumours. The authors suggested
that Collagen 7 functioned as a TGFβ1 suppressor and,
again, the data are consistent with an αvβ6-dependent
act ivat ion of TGFβ1 act ivat ing a fibroblast- to-
myofibroblasts transition, which subsequently increases
the secretion of fibronectin.
Eberlein et al. (2015) investigated the effects of the co-
culture of a panel of non-small cell lung cancer cell lines with
fibroblasts and found that those cancer lines that promoted
trans-differentiation of fibroblasts to myofibroblasts
(αSMA–positive) expressed E-cadherin, EpCAM and αvβ6.
Blockade of αvβ6 with 264RAD or of TGFBR1 with a small
molecule inhibitor blocked myofibroblast formation.
Interestingly, if the inhibitors were added 3 days after co-cul-
ture, only the TGFBR1 inhibitor suppressed SMA expression,
suggesting that, whereas αvβ6 initiates the process, once
started, αvβ6-independent processes maintain TGFβ activa-
tion (Eberlein et al. 2015).
Dutta et al. (2015) reported the novel αvβ6 regulation of
TGFβ1 signalling in prostate cancer cells. Generating a panel
of PC3 prostate cancer cells expressing αvβ6 or αvβ6/
β3cyto or αvβ3/β6cyto chimeras, these authors reported that
αvβ6 co-precipitated with TGFBRII, a relationship that re-
quired the cytoplasmic tail of β6 and that physical association
was required for the TGFβ1-dependent upregulation of
SMAD3, which in turn upregulated MMP2. This is the first
report suggesting that αvβ6 regulates TGFβ1 signalling via
physical association with the TGFβ1 receptor complex. The
determination of whether this unique observation is seen in
other cell models will be of interest.
Thus, numerous examples link the αvβ6-dependent acti-
vation of TGFβ1 as a promoter of pre-clinical tumour pro-
gression. Therefore, we must consider it likely that, in clinical
studies in which poor overall survival has been linked to the
over-expression of αvβ6, TGFβ1 activation by αvβ6 is a
tumour-driver. Since Bates et al. (2005) reported that high
αvβ6 correlates with poor survival in colon cancer, similar
observations have been reported for non-small cell lung can-
cer (Elayadi et al. 2007), cervical cancer (Hazelbag et al.
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2007) and breast cancer (Moore et al. 2014). Each of these
studies had sufficient clinical samples and follow-up data to
establish survival relationships. Other studies with smaller
numbers of tissue samples also reported high fractions
of carcinomas positive for αvβ6 including ovarian (100 %,
Ahmed et al. 2002; 33 %, Van Aarsen et al. 2008), pancreatic
(100 %, Sipos et al. 2004), oesophageal (68 %, Van Aarsen
et al. 2008) and skin (84 %, Van Aarsen et al. 2008).
Eventually, we will establish the role of αvβ6 and, indeed,
the role of other αv integrins in activating TGFβ1 in each of
these cancers and the subsequent effects on tumour growth
and spread.
Notably, if cancer tissues retain the tumour-suppressive
responsiveness to TGFβ1, then the blockade of αvβ6 could
potentially promote cancer, as was described in a transgenic
mouse model of pancreatic cancer (Hezel et al. 2012). In fact,
early studies showed that, in normal tissues, αvβ6 was
tumour-suppressive through its activation of TGFβ1. Thus,
knockout of the β6 gene (itgb6) in mice was associated with
a mild inflammatory response in skin and lung (Huang et al.
1996) and with a propensity for the spontaneous formation of
certain cancers in up to 25 % of itgb6-null mice (Ludlow et al.
2005), patterns that mimicked a mild form of global TGFβ1
knockout mouse (Shull et al. 1992). These unrelated observa-
tions might have indicated that theαvβ6-dependent activation
of TGFβ1 in part regulated tumour immune surveillance, as
shown subsequently forαvβ8 (Travis et al. 2007). Certainly, a
recent study reported that αvβ6 and αvβ8 on keratinocytes
regulated the retention time of dendritic cells and memory T
cells in the skin and colon by locally activating TGFβ1
(Mohammed et al. 2016).
Therefore, overall, whereas some data are conflicting,
strong evidence has been provided that, in some cancer tis-
sues, αvβ6 is associated with tumour promotion, in part via
the activation of latent TGFβ1, which subsequently regulates
elements in the stroma, including the number of
myofibroblasts and blood vessels. In addition, some αv
integrins clearly regulate the behaviour of inflammatory and
immune cell populations. It is through these three processes,
described below, that the αv integrin-dependent activation of
TGFβ1 can impact most strongly on the stroma. Of note, the
principal reason that most of the available data linking αv
integrins to TGFβ-regulation of cancer involve αvβ6 is prob-
ably attributable to the absence of widely available reagents
that specifically detect and inhibit integrins αvβ8 and αvβ1;
this means their distribution and activity in cancer remains
unknown. Moreover, whereas αvβ3 has been reported to reg-
ulate TGFβ1 signalling negatively in endothelial cells of
healing wounds (Reynolds et al. 2005), the widespread ex-
pression of αvβ3 and αvβ5 on multiple cell types makes
the determination of their specific activities difficult to prove
by using global antibody blockade and will require genetic
ablation in specific cell types.
3) Myofibroblasts/CAFs promote cancer progression by
multiple mechanisms
TGFβ1 is the most powerful activator of the trans-
differentiation of fibroblasts into myofibroblasts. Thus, those
integrins that activate TGFβ1 can also induce myofibroblast
formation and therefore can be considered responsible for
myofibroblast-dependent activities that include matrix-remod-
elling, matrix-stiffening and cancer promotion.
All tissues have resident fibroblasts that maintain the tissue
homeostasis of matrix content and whose presence primes
tissues to respond to wounding or infection. However,
TGFβ1 induces fibroblasts to adopt a contractile wound-
repair phenotype and genotype termed a myofibrobast.
When this trans-differentiation occurs in the tumour microen-
vironment, the myofibroblasts are also known as activated
fibroblasts, cancer-associated fibroblasts (CAFs) or tumour-
associated fibroblasts (TAFs). Not all CAFs are derived from
resident cells. Thus, TGFβ1 can induce some non-fibroblast
cells, including adipocytes (Jotzu et al. 2010) and circulating
bone-marrow-derived suppressor cells (Weber et al. 2015), to
trans-differentiate into cancer-associated myofibroblasts.
Integrins can also potentially regulate TGFβ signalling af-
ter TGF activation has occurred. In fibroblasts derived from
human oral and dermal tissues, anti-αvβ3 or αvβ5 integrin
antibody blockade in the presence of exogenous active
TGF-β1 inhibits the expression of α-SMA and collagen gel
contraction. Furthermore, in renal fibroblasts, only αvβ5
blockade and not αvβ3 is sufficient to reproduce these same
inhibitory effects, suggesting that the differentiation of fibro-
blasts that are derived from different tissues are not necessarily
regulated by the same integrin (Lewis et al. 2004). The mech-
anisms regarding the reasons that αvβ3 and αvβ5 are re-
quired for TGFβ1-induced trans-differentiation to the
myofibroblast phenotype have not been established.
Above, we have discussed the way that, by increasing the
contraction of the extracellular matrix, myofibroblasts in-
crease the likelihood of activating latent TGFβ1. However,
myofibroblasts secrete a huge number of proteins that further
enhance cancer progression including extracellular matrix
proteins, proteases, growth factors, cytokines and chemokines
(for a review, see Miles and Sikes 2014).
Surgeons and pathologists have known for many years that
most cancers are stiffer to the touch than the surrounding
normal tissues and we now know that the cells responsible
for this increased stiffness are the collagen-producing contrac-
tile myofibroblasts. Originally, the stiffness was assumed to be
an effort on the part of the host to wall off the mutant tissue as
a means of protection. Indeed, recent studies of pancreatic
cancer suggest that some types of pancreatic fibroblast are
tumour-suppressive (Rhim et al. 2014; Ozdemir et al. 2014).
However, clearly, tumour cells often secrete latent TGFβ1 and
can promote the generation of myofibroblasts and, thus, we
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can reasonably assume that they derive benefit from activating
fibroblasts to myofibroblasts. We have only recently con-
firmed that a stiff extracellular matrix can signal tumour cells
to promote their growth and survival (for a review, see Malik
et al. 2015).
Myofibroblasts secrete many different types of collagens
(discussed in Miles and Sikes 2014) that they form into fibrils
in the matrix. A positive relationship exists between the thick-
ness and orientation of the collagen fibrils and the invasive
behaviour of cancers (Provenzano et al. 2006).Myofibroblasts
can promote the cross linking of collagen fibres through the
secretion of lysyl oxidases (LOX), which can covalently
crosslink collagens and elastin. Many studies have reported
that levels of LOX correlate with increased invasion, metasta-
sis and poor survival in pancreatic cancer (Miller et al. 2015),
astrocytoma (da Silva et al. 2015), breast cancer
(Friesenhengst et al. 2014) and liver cancer (Zhu et al.
2015a). Such observations identify LOX and LOX-like en-
zymes as potential therapeutic targets.
Myofibroblasts also secrete periostin that acts in several
ways to promote cancer. First, it can bind to fibronectin
through its FAS domain and to bone morphogenetic protein-
1 (BMP-1) through its EMI domain. This anchors BMP-1 in
the matrix where it can promote the maturation of the pre-Lox
propeptide into the mature Lox enzyme, enabling it to gener-
ate collagen crosslinks that can contribute to increase matrix
stiffening (Maruhashi et al. 2010; Garnero 2012). Periostin is
also a ligand for αv integrins. Periostin promotes the prolifer-
ation of melanoma cells via binding integrin αvβ3 and αvβ5
and activating the p43/p44 MAPK signalling pathway
(Kotobuki et al. 2014). Moreover, the addition of TGFβ-
neutralising antibody to cultures of fibroblasts in melanoma-
cell-conditioned media prevents the upregulation of periostin
(Kotobuki et al. 2014). Periostin also seems to drive oesoph-
ageal cancer. Thus, Underwood and colleagues (2015) report-
ed that the number of αSMA-positive myofibroblastic CAFs
in oesophageal carcinoma correlated with poor overall surviv-
al. Since up to 68 % of oesophageal cancers are reported to be
αvβ6-positive (Van Aarsen et al. 2008), one could speculate
that αvβ6 integrin induces these αSMA-positive cells via
TGFβ1 activation. Moreover, the secretion of periostin by
these oesophageal CAFs bind to αvβ3 and αvβ5 on oesoph-
ageal cancer cells activating PI3 kinase signalling and promot-
ing oesophageal cancer cell invasion. Genetic ablation of the
periostin gene (POSTN) in the CAFs eliminates the pro-
invasive effects on the oesophageal cancer cells.
Additionally, clinical material has shown an exact correlation
between the expression of periostin and αSMA (Underwood
et al. 2015). Given its dual role as a component of matrix
stiffening and pro-invasive signalling, many recent reports
have unsurprisingly linked periostin to cancer promotion and
poor survival (Landre et al. 2016; Qin et al. 2016; Sung et al.
2016; Xu et al. 2016; Fukuda et al. 2015) suggesting that it is
also a good potential therapeutic target for suppressing cancer
development.
TGFβ1-treated fibroblasts can secrete osteopontin (Corallo
et al. 2014), an RGD-containing integrin ligand implicated in
the promotion of tumour growth, EMTand metastasis (Platzer
et al. 2011; Kothari et al. 2016). Thus, increased osteopontin
correlates with increased metastasis and often poor survival in
multiple types of cancer including laryngeal squamous cell
carcinoma (Chen et al. 2015), melanoma (Kiss et al. 2015),
nasopharyngeal carcinoma (Hou et al. 2015) and breast cancer
(Xu et al. 2015). Lenga et al. (2008) reported that osteopontin
was required for TGFβ1 transdifferentiation of cardiac fibro-
blasts tomyofibroblasts, whereasWeber et al. (2015) provided
evidence that osteopontin induced bone-marrow-derived mes-
enchymal suppressor cells to become myofibroblasts.
TGFβ1 induces the transcription of the CCN family of
matricellular proteins including CCN1/cysteine-rich protein
61 (CYR61) and CCN2/connective tissue growth factor
(CTGF), which affect a variety of cell types, including fibro-
blasts, through binding to integrins (Leask 2013). CYR61
appears to function as a tumour suppressor or promoter de-
pending on which integrin is engaged.The binding of CYR61
to α6β1 generates senescence-inducing reactive oxygen spe-
cies in fibroblasts, associated with reduced TGFβ1 expres-
sion, or induces p53-dependent apoptosis, therefore protecting
against aberrant cell proliferation and fibrosis (Jun and Lau
2010; Lau 2011). In contrast, the binding of CYR61 to αvβ3
or αvβ5 stimulates prostate cancer cell growth and metastasis
(Grzeszkiewicz et al. 2001) or fibroblast migration (Sun et al.
2008). In oesophageal cancers, CYR61 mRNA is an indepen-
dent poor prognostic factor (Huang et al. 2009).
CTGF promotes breast cancer EMTand increases collagen
type I fibre deposition (Zhu et al. 2015b). In a separate study,
the pro-fibrotic activity of CTGF was observed via a positive
feedback loop, binding αvβ3 on fibroblasts and further stim-
ulating αvβ3 upregulation, collagen synthesis and contrac-
tion, thereby enhancing the potential for increased TGFβ ac-
tivation (Hu et al. 2014). In addition, intermediary proteins
provide an extra level of regulation of TGFβ1 and integrin
autocrine signalling. For example, TGFβ1 induces secretion
of protease inhibitor plasminogen activator inhibitor-1 (PAI-
1), which in turn can bind to and promote αvβ3
internalisation. Therefore, PAI-1 knockout in mouse embry-
onic fibroblasts results in reduced αvβ3 endocytosis, elevated
transmembrane TGFβ type II receptor expression and en-
larged focal adhesion sites, correlating with a three-fold rise
in Smad2/3 expression (Pedroja et al. 2009).
Thus, these data and those of others (Beacham and
Cukierman 2005; Sherman et al. 2014) suggest that a
TGFβ1-activated myofibroblast/CAF-rich tumour stroma is
tumour-promoting. However, conflicting data have also been
presented. A recent study reported that the global depletion of
replicating αSMA-positive myofibroblasts/CAFs in two
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transgenic mouse models of pancreatic ductal adenocarcino-
ma (PDAC) enhanced the development of undifferentiated
pancreatic cancers. This was associated with a significant re-
duction in fibrosis, the down-regulation of infiltrating macro-
phages and the upregulation of immunosuppressive CD4+/
FoxP3+ regulatory T cells (TRegs; Ozdemir et al. 2014). In
separate studies, Rhim et al. (2014) examined the role of the
sonic hedgehog signalling pathway, as sonic hedgehog (Shh)
can promote a fibroblast-rich microenvironemnt in cancer.
They showed that either genetic ablation of sonic hedgehog
protein or pharmacological inhibition of the downstream
smoothened protein resulted in the development of more ag-
gressive, highly vascularised, PDAC tumours that had a sig-
nificant reduction in stromal cell density (Rhim et al. 2014). In
contrast, recent work demonstrated that TGFβ1 drove a pro-
tumourigenic phenotype in pancreatic cancer (Principe et al.
2016). Using the Elastase-promoter driven KRas G12D
mouse, which develops pancreatic neoplasia, Principe et al.
(2016) eliminated epithelial TGFβ signalling selectively by
over-expression of a dominant negative TGFBR2 (DN
TGFBR2) construct or eradicated TGFβ1 signalling globally
by generating tgfbr1+/−mice. Mice deficient in TGFβ signal-
ling in their epithelia showed enhanced disease progression,
consistent with the loss of TGFβ1-dependent tumour suppres-
sion. In contrast, the global knockout mice showed signifi-
cantly reduced tumour progression, suggesting that TGFβ1
signalling in the stroma normally promoted pancreatic neopla-
sia. Whereas none of these recent studies included investiga-
tions of integrin expression, their contrasting observations
concerning the stromal control of pancreatic fibrosis suggest
that the genetic background of the transgenic models is a ma-
jor determining factor for the outcome of such studies and that
we still have much to discover.
4) TGFβ1 enhanced angiogenesis
Angiogenesis describes the formation of new blood vessels
from pre-existing branches and promotes tumour progression,
because blood vessels provide the essential nutrients required
by growing tumours and facilitate metastasis (Chung and
Ferrara 2011). TGFβ1 can promote angiogenesis (Vinals
and Pouyssegur 2001; Li et al. 2001) and thus local activation
of TGFβ by αv integrins in cancer is likely to promote the
development of blood vessels. However, TGFβ-mediated ef-
fects are concentration-dependent, as low concentrations can
promote blood vessel formation, whereas higher amounts are
anti-angiogenic (Orlova et al. 2011). Moreover, TGFβ-
concentration-dependent actions may occur via the stimulation
of different TGFβ receptor signalling pathways. Activation of
the activin-receptor-like kinase (ALK1) induces endothelial
cell proliferation and migration via the phosphorylation of
Smad 1/5, whereas the activation of the ALK5/Smad 2 cascade
inhibits this effect on endothelial cells (Goumans et al. 2002).
Integrins αvβ3 and αvβ5 (Weis and Cheresh 2011) and
αvβ8 (Zhu et al. 2002; Arnold et al. 2012) are all reported to
regulate angiogenesis but only αvβ8 is described to do so
through TGFβ1 activation. The role of αvβ3 and αvβ5 in
angiogenesis is under debate. Both integrins are upregulated
on endothelial cells of new blood vessels and promote their
migration in vitro and their blockade with antibodies have
suppressed blood vessel growth in a variety of pre-clinical
studies (Gutheil et al. 2000; Friedlander et al. 1995).
However, genetic ablation of itgb3, itgb5 or both simulta-
neously accelerates tumour vasculature growth and develop-
ment, attributable to the increased expression of vascular en-
dothelial growth factor receptor 2 (VEGFR2) and sensitivity
to VEGF-A (discussed by Silva et al. 2008) suggesting that
these integrins are not required for blood vessel formation but
regulate their rate of growth.
Integrinαvβ8-knock out mice demonstrate severe vascular
defects resulting in haemorrhaging, predominantly in the cen-
tral nervous system, with a large proportion of mice dying
shortly after birth and some earlier (Zhu et al. 2002).
Knockout of β8 in Muller glia or retinal ganglion cells pro-
motes vascular abnormalities that match retinal TGFβ1-
knockout, suggesting αvβ8 is necessary for TGFβ1–depen-
dent retinal maturation (Arnold et al. 2012). Integrin αvβ8 is
not expressed on endothelial cells but is expressed on neural
peri-vascular astrocytic cells where it binds and activates la-
tent TGFβ1, which promotes increased stability and differen-
tiation of blood vessels (Cambier et al. 2005).
Analysis of αvβ8 function was examined in astrocytoma
by using orthotopic transgenic cell lines. Intra-cranial injec-
tion of human β8-low astrocytoma cells (U87) resulted in
haemorrhagic tumours, whereas β8-positive cells formed mi-
croscopic tumours with well-defined vasculature. Orthotopic
injection again showed a well-established vasculature in β8
wild-type transformed astrocytes and a disorganised
haemorrhagic vasculature in the absence of β8. Moreover,
endothelial cells examined from β8−/− mice express approxi-
mately two- to three-fold less phospho-Smad 2 and 3 suggest-
ing that less active TGFβ is present inβ8-null mice. However,
no significant difference was seen in tumour volume in β8−/−
and wild-type mice, although the former exhibited reduced
survival rates because of haemorrhage (Tchaicha et al.
2010). In separate studies, the over expression of β8 in U87
was shown to result in brain tumours with organised non-
haemorrhagic vasculature and this affect required the activa-
tion of latent TGFβ1 (Tchaicha et al. 2011).
A key mediator between intracellular TGFβ signalling and
transmembrane integrins in endothelial cells is endoglin, a
TGFβ superfamily accessory receptor that is expressed in
the angiogenic vessels of brain, lung, breast, stomach and
colon cancers (Minhajat et al. 2006). In response to murine
embryonic endothelial cells binding fibronectin via integrin
α5β1, TGF-β1-induced Smad1/5/8 phosphorylation
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increases in an endoglin-dependent manner. Reciprocally,
endoglin is necessary for TGFβ1-induced phosphorylation
of β1 integrin threonines 788/789 and FAK, whereas
fibronectin/endoglin cross-talk maintains endothelial cell sur-
vival (Tian et al. 2012). Perhaps unsurprisingly, endoglin is a
prognostic marker in colorectal cancers with correlation to
lymph node and liver metastases (Saad et al. 2004).
5) TGFβ regulates inflammatory and immune cells to
modulate cancer progression
When integrin-LAP binding is prevented by an RGD to
RGE mutation in LAPβ1, mice exhibit a multi-organ inflam-
matory response that mirrors global TGFβ1-knockout (Yang
et al. 2007). Since the effective absence of both αvβ6 and
αvβ8 also results in multi-organ inflammation, recapitulating
global TGFβ1 deficiency, this suggests that none of the other
αv integrins are required to regulate these particular TGFβ1-
dependent effects (Aluwihare et al. 2009). However, these
studies have only assessed the integrin-dependent activation
of latent TGFβ during development and birth but not in adult
mice or in pathological situations such as cancer. Thus, the
possibility exists that the activation of TGFβ by any αv
integrin can influence local inflammatory and immune cells
in adult animals. This is important as TGFβ1 promotes im-
munosuppressive effects on various effector T-cells (for a
review, see Travis and Sheppard 2014) and induces tumour-
promoting phenotypes in both neutrophils and macrophages.
Travis et al. (2007) reported that the loss of αvβ8 on den-
dritic cells results in inflammatory bowel disease (Travis et al.
2007). The effect is attributable to an inability of αvβ8-
deficient dendritic cells to activate TGFβ locally and thus to
promote the differentiation of naïve T-cells into TReg via
Foxp3 transcription factor (Chen et al. 2003). TReg cells are
a subpopulation of CD4+ CD25+ T cells whose functions en-
compass the immunosuppression of effector T-cells including
the maturation of CD8 cytotoxic T cells (McNally et al. 2011)
and maintaining immunological tolerance (discussed in Travis
and Sheppard 2014). Moreover, these differentiated cells sup-
press their production of helper T cell cytokines, instead se-
creting TGFβ1, further amplifying TGFβ1 signalling and its
immunosuppressive effects (Chen et al. 2003). These data
correlate with the observation that high levels of TRegs in
cancer tissues are associated with poor overall survival from
several types of solid cancer (Shang et al. 2015). TReg accu-
mulation correlates with tumour progression in breast, ovarian
and pancreatic cancer, although the effect of TRegs on prog-
nosis depends on factors such as tumour location and inflam-
matory status (Oleinika et al. 2013; Schmidt et al. 2016).
Although, to date, no pre-clinical studies have made a detailed
examination of immune infiltrates in response to blockade of
αv integrins, carcinomas expressing αvβ6, astrocytomas ex-
pressing αvβ8 and desmoplastic tumour myofibroblasts
expressingαvβ5 and αvβ1, are likely to regulate TReg levels
in the TME.
TGFβ1 also promotes the formation of tumour-promoting
M2 tumour-associated macrophages and N2 tumour-
associated neutrophils (Gong et al. 2012; Fridlender et al.
2009). Macrophages present as having BM1^ anti-tumour or
BM2^ tumour-promoting characteristics. Macrophages co-
cultured with ovarian carcinoma cells significantly increase
the transcription of TGFβ1, TGFBRI and TGFBRII
(Hagemann et al. 2006). TGFβ1 stimulates monocyte recruit-
ment and alters the inflammatory gene expression profile of
macrophages by increasing metastasis-associated interleukin-
6 (IL-6) and suppressing cytokines such as IL-10 and
chemoattractants CCL3 and CCL4 (Krstic and Santibanez
2014). TGFβ1 stimulation of macrophages also promotes an-
giogenesis under hypoxic conditions by the elevated produc-
tion of VEGF, MMP-9 and VEGF receptor Flk-1 expression
(Jeon et al. 2007). High levels of M2 macrophages correlate
with poor survival from cancer including pancreatic and cer-
vical cancer (Petrillo et al. 2015; Hu et al. 2016), gastric cancer
spread (Yamaguchi et al. 2015) and relapse after chemothera-
py (Hughes et al. 2015). Indeed, pre-clinical studies suggest
M2 cells can promote metastasis (Ding et al. 2015; Wu et al.
2015; Yang et al. 2015).
Similarly, tumour-associated neutrophils polarised to the
N2 state are also pro-tumourigenic as reviewed recently
(Sionov et al. 2015). Thus, depletion of N2 neutrophils within
TGFβ1-rich mouse tumours significantly reduces tumour
size, supporting the concept that separate populations of
anti-tumour and pro-tumour neutrophils are regulated by ac-
tive TGFβ (Fridlender et al. 2009). Recent studies by Sagiv
et al. (2015) suggested neutrophils can be segregated accord-
ing to their cell density, whereby low-density neutrophils are
tumour-promoting and high-density neutrophils are tumour-
suppressive. The authors discovered that tumour progression
in mice correlated with an increase in the fraction of circulat-
ing low-density neutrophils, eventually becoming the domi-
nant fraction; in tumour-free mice, 95 % of circulating neutro-
phils had the high-density phenotype. Moreover, the authors
discovered that TGFβ1was required and sufficient to promote
the transition of the high-density neutrophils into the tumour-
supportive low-density neutrophils. Functionally, the high-
density neutrophils suppressed tumour growth and were cyto-
toxic in vitro towards tumour cells. In contrast, the low-
density neutrophils were deficient in cytotoxic H2O2, exhibit-
ed reduced chemotaxis towards the tumour and were less
phagocytic. In addition, low-density neutrophils produced less
inflammatory cytokines and were able to suppress the prolif-
eration of CD8+ cytotoxic T-cells and thus effectively promot-
ed tumour growth.
Overall, TGFβ has tumour-promoting and -immuno
suppressive effects on several immune cell types in the tumour
stroma. However, more studies are needed to determine what
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proportion of TGFβ activation of immune cells in the tumour
stroma is solely integrin-dependent, so that therapeutic
targeting of relevant integrins can suppress the pathogenic
effects of active TGFβ on tumour-promoting immune
components.
Future of drug targeting integrin-dependent
activation of TGFβ in cancer
In this review, we discussed the indirect effects on tumour
progression exerted by αv integrins because of their ability
to activate latent TGFβ1. However, all αv integrins can signal
via their cytoplasmic tails and some (e.g., αvβ3 and αvβ6)
can generate pro-tumourigenic signals including those for
growth, survival and the secretion of proteases, factors that
can enhance tumour progression. Thus, the fraction of an
integrin’s ability to promote cancer via its cytoplasmic tail
versus its ability to activate TGFβ is unclear. Regardless, the
direct inhibition of the ligand-binding site of αv integrins is
sufficient to block their capacity to activate TGFβ1 and to
generate survival signals and has been used in pre-clinical
and clinical studies (Eberlein et al. 2013; Marsh et al. 2008).
Of the integrins that can potentially activate TGFβ1, only
αvβ3-specific antibodies and peptides have been used in
humans as part of anti-cancer therapies (Posey et al. 2001;
Hersey et al. 2010; Khasraw et al. 2016) but none has
achieved significant clinical success. Whereas some cancers
express high levels of αvβ3 (e.g., melanoma and glioblasto-
ma), the discovery that αvβ3 negatively regulates the endo-
thelial cell growth factor receptor VEGFR2 means that block-
ade of αvβ3 will result in increased angiogenesis and tumour
growth (see above). However, Reynolds et al. (2009) reported
that sub-therapeutic concentrations of Cilengitide, an αvβ3/
αvβ5 peptide inhibitor, enhanced angiogenesis and, as new
blood vessels tend to be leakier,Wong et al. (2015) used this to
show that pre-dosing with Cilengitide improved drug accessi-
bility to a variety of experimental tumours. Thus, targeting
αvβ3 may still be therapeutic but possibly not by inhibiting
TGFβ1 activation. Recently, Merck published results of the
POSEIDON trial. Their pan-αv blocking humanised antibody
Abituzumab was compared with the standard of care
(cetuximab, an EGFR inhibitor and irinotecan, a topoisomer-
ase 1 inhibitor) in metastatic colorectal cancer (CRC; Elez
et al. 2015). Data from the whole cohort showed that combin-
ing Abituzumab with cetuximab and irinotecan provided no
significant survival benefit versus the cetuximab and
irinotecan combination alone. However, when the expression
levels of the different αv inetrgins on the tumour tissue were
assessed, the data showed that the risk of death for patients
with high αvβ6 (above the median histological score) was
reduced by 59 % by the addition of Abituzumab to the treat-
ment regimen. Overall, the data suggest that targeting αvβ6
with inhibitory antibodies could be positively therapeutic for
patients whose cancer over-expresses αvβ6. It is worth
recalling that, in those studies with large enough patient co-
horts, high αvβ6 correlated with poor survival and, thus, the
identification of those patients by the simple immunohisto-
chemistry of biopsies might be sufficient to select only the
likely responders to αvβ6-blocking therapy.
Antibody targeting of integrin αvβ6 in humans is work in
progress. Thus, Biogen-Idec have developed the humanised
αvβ6-blocking monoclonal antibody STX-100, which is be-
ing used in idiopathic fibrosis studies (clinicaltrials.gov#
NCT01371305). AstraZeneca-Medimmune have developed
the entirely human monoclonal antibody 264RAD, which
blocks αvβ6 but also has some blocking activity of αvβ8
(Eberlein et al. 2013). To date, this antibody has not entered
clinical trials but speculation regarding its potential effects is
of interest, given the results of the POSEIDON study, which
has suggested that the blockade of αvβ6 is likely to be ther-
apeutic in colon cancer (Elez et al. 2015). Thus, Eberlein and
colleagues (2013) reported the complete suppression of the
growth of xenografts of the oral squamous carcinoma cell line
Detroit-562 at doses of 5 and 20 mg/kg 264RAD and this
correlates with the loss of expression of the target integrin
αvβ6 on the residual tumour. Moore and colleagues (2014)
also noted that 264RAD-induced breast tumour xenograft
suppression also correlates with loss of αvβ6 expression.
Since antibody 264RAD operates as a ligand mimetic, we
consider it worth noting that, in a recent study, GSK also
reported, from in vitro studies, that the exposure of cells to
LAP or A20FMDV2, a high-affinity αvβ6-specific 20-
amino-acid peptide derived from foot-and-mouth-disease vi-
rus, causes a rapid ligand-induced internalisation of αvβ6 but
a slower re-expression (Slack et al. 2016). Thus, perhaps
ligand-induced transient loss of cell-surface αv integrins
may be a goal of future anti-cancer therapeutics, since this
might be more efficient as a means of suppressing local
TGFβ1 activation than attempting to achieve high enough
concentrations of an extracellular inhibitor that can complete-
ly suppress the binding of the integrin to LAP.
Antibody blockade of αvβ6 may not be the only therapeu-
tic strategy for regulating TGFβ1 activity. Merck has gener-
ated small-molecule inhibitors of αvβ6, αvβ5 and αvβ3
(Goodman et al. 2002) and GSK have recently produced
naphtyridine-derivative small molecule antagonists of αvβ6
(Patent WO 2014154725 A1). Whereas neither company has
used their compounds clinically, if these small molecules can
also operate as ligand-mimetics, they might compare
favourably with inhibitory antibodies that are likely to have
better pharmacokinetics.
We should also mention the potential added value of the
therapeutic targeting of integrins as a means of regulating
TGFβ1 activity in cancer and fibrosis as opposed to directly
targeting the TGFβ1 signalling pathway. Thus, the blockade
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of TGFβ receptors with small-molecule kinase inhibitors or of
TGFβ itself with inhibitory antibodies would promote a
whole body inhibition of TGFβ activity, whereas integrin
blockade produces local control of TGFβ activation. Since,
as mentioned above, TGFβ is required for normal tissue reg-
ulation, integrin targeting would minimise off-target effects.
Concluding remarks
Integrin activation of latent TGFβ1 can be a significant com-
ponent of the way that tumours develop and respond to their
stroma. First, the ability of αvβ6 and αvβ8 integrins to acti-
vate TGFβ1 was established as a major platform for the nor-
mal homeostatic regulation of TGFβ1 activity. Second, the
discovery that both αvβ5 and αvβ1 on fibroblasts also acti-
vated latent TGFβ1 in a biomechanical way (like αvβ6) in-
dicated that stromal cells could also contribute to local TGFβ1
activity. Finally, the additional revelation that increasing stro-
mal stiffness reduced the activation threshold for the force
required to activate TGFβ1 introduced the likelihood that
pathological stromal fibrosis was driven by an amplification
of activation of abundant latent TGFβ1 in the matrix generat-
ed by multiple αv integrins. However, although multiple
mechanisms exist by which TGFβ1 modulates the tumour
microenvironment to promote cancer (Fig. 2; Pickup et al.
2013), we still have a relative paucity of empirical in vivo data
firmly establishing those TGFβ1-driven stromal responses
that are the direct result of the αv integrin activation of
TGFβ. We clearly lack certain reagents and model systems
that would allow us fully to characterise those αv integrins
that activate TGFβ at various times and stages in cancer pro-
gression. Thus, we lack certain tissue-specific inducible αvβ
integrin knockout mice (including itgb6) that would permit
researchers, over the course of the development of a cancer,
temporally to eliminate an αvβ integrin and examine its con-
tribution to TGFβ1-driven tumourigenesis. Subsequently, by
introducing therapeutics to these same integrins, we could
establish when the most effective therapeutic window occurs
and also whether cancers reach a point at which the targeting
of integrin-dependent TGFβ1 activation is no longer effec-
tive, perhaps because so many processes (multiple integrins,
tissue stiffness, proteases) are simultaneously able to activate
the latent TGFβ. We have mentioned the absence of
Fig. 2 Contribution of integrin-mediated TGFβ1 activation of
pro-tumour mechanisms via regulation of cells of the immune system,
promotion of epithelial-mesenchymal transition and angiogenesis.
Immune system 1) Active TGFβ stimulates naive T-cell-to-Treg differen-
tiation (top). Tregs exhibitαvβ8-mediated TGFβ1 activation, amplifying
the differentiation of other naive T-cells. Tregs suppress anti-tumour T-
cell responses. Tumour cell integrins mediate TGFβ1 activation (bottom).
Active TGFβ1 stimulates macrophage and neutrophil pro-tumour
responses. Epithelial-to-mesenchymal transition TGFβ1 stimulation of
epithelial cells represses epithelial gene signatures, e.g., cell-cell adhesion
molecule E-cadherin (top). This promotes a more mesenchymal invasive
cell phenotype (bottom). Angiogenesis TGFβ1 stimulation of tumour
cells increases VEGF expression, which binds to its receptor on local
endothelial cells. Integrin αvβ3 promotes activation and recycling of
VEGFR (left). The αvβ8-mediated activation of TGFβ1 facilitates
TGFβ activation of local endothelial cells, which can promote or inhibit
angiogenesis via separate TGFβ receptors (right)
668 Cell Tissue Res (2016) 365:657–673
antibodies that would allow us to determine the expression of
αvβ1 and αvβ8 in tissues and, similarly, no αvβ8 blocking
antibodies are available for pre-clinical studies. Therefore, as
these reagents become available, we may better be able to
delineate an appropriate clinical strategy by the study of the
temporal increase in the number of diverse mechanisms for
latent TGFβ activation that accumulate during cancer devel-
opment. However, although we may lack some data that will
refine our treatments, αv integrins must now be considered as
bona fide targets for anti-TGFβ therapy in fibrosis and cancer.
Open Access This article is distributed under the terms of the Creative
Commons Attr ibution 4.0 International License (http: / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez
MV, Mok S, Baker MS (2002) Overexpression of alpha(v)beta6
integrin in serous epithelial ovarian cancer regulates extracellular
matrix degradation via the plasminogen activation cascade.
Carcinogenesis 23:237–244
Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ,
Gomm JJ, Dreger SA, Dickinson S, Edwards DR, Pennington CJ,
Sestak I, Cuzick J, Marshall JF, Hart IR, Jones JL (2014) Altered
microenvironment promotes progression of preinvasive breast can-
cer: myoepithelial expression of alphavbeta6 integrin in DCIS iden-
tifies high-risk patients and predicts recurrence. Clin Cancer Res 20:
344–357
Aluwihare P, Mu Z, Zhao Z, Yu D,Weinreb PH, Horan GS, Violette SM,
Munger JS (2009) Mice that lack activity of alphavbeta6- and
alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and
Tgfb3-null mice. J Cell Sci 122:227–232
Annes JP, Chen Y, Munger JS, Rifkin DB (2004) Integrin alphaVbeta6-
mediated activation of latent TGF-beta requires the latent TGF-beta
binding protein-1. J Cell Biol 165:723–734
Arnold TD, Ferrero GM, Qiu H, Phan IT, Akhurst RJ, Huang EJ,
Reichardt LF (2012) Defective retinal vascular endothelial cell de-
velopment as a consequence of impaired integrin alphaVbeta8-
mediated activation of transforming growth factor-beta. J Neurosci
32:1197–1206
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218
Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H,
Sheppard D, Oettgen P, Mercurio AM (2005) Transcriptional acti-
vation of integrin beta6 during the epithelial-mesenchymal transition
defines a novel prognostic indicator of aggressive colon carcinoma.
J Clin Invest 115:339–347
Beacham DA, Cukierman E (2005) Stromagenesis: the changing face of
fibroblastic microenvironments during tumor progression. Semin
Cancer Biol 15:329–341
Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT,
Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996)
Localization of matrix metalloproteinase MMP-2 to the surface of
invasive cells by interaction with integrin alpha v beta 3. Cell 85:
683–693
Cambier S, Gline S, Mu D, Collins R, Araya J, Dolganov G, Einheber S,
Boudreau N, Nishimura SL (2005) Integrin alpha(v)beta8-mediated
activation of transforming growth factor-beta by perivascular astro-
cytes: an angiogenic control switch. Am J Pathol 166:1883–1894
ChenW, JinW, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G,Wahl
SM (2003) Conversion of peripheral CD4+CD25- naive T cells to
CD4+CD25+ regulatory T cells by TGF-beta induction of transcrip-
tion factor Foxp3. J Exp Med 198:1875–1886
Chen J, Zhu C, He Z, Geng M, Li G, Tao X, Zhang F (2015) Association
of OPN overexpression with tumor stage, differentiation, metastasis
and tumor progression in human laryngeal squamous cell carcino-
ma. Int J Clin Exp Med 8:7116–7124
Chung AS, Ferrara N (2011) Developmental and pathological angiogen-
esis. Annu Rev Cell Dev Biol 27:563–584
Corallo C, Volpi N, Franci D, Montella A, Biagioli M, Mariotti G,
D’Onofrio F, Gonnelli S, Nuti R, Giordano N (2014) Is osteopontin
involved in cutaneous fibroblast activation? Its hypothetical role in
scleroderma pathogenesis. Int J Immunopathol Pharmacol 27:97–102
da Silva R, Uno M, Marie SK, Oba-Shinjo SM (2015) LOX expression
and functional analysis in astrocytomas and impact of IDH1 muta-
tion. PLoS One 10:e0119781
Dallas SL, Sivakumar P, Jones CJ, Chen Q, Peters DM, Mosher DF,
Humphries MJ, Kielty CM (2005) Fibronectin regulates latent
transforming growth factor-beta (TGF beta) by controlling matrix
assembly of latent TGF beta-binding protein-1. J Biol Chem 280:
18871–18880
DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, Hart IR,
Howard MJ, Marshall JF (2007) Structure-function analysis of Arg-
Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem
282:9657–9665
Ding L, LiangG, Yao Z, Zhang J, Liu R, Chen H, Zhou Y,WuH,Yang B,
He Q (2015) Metformin prevents cancer metastasis by inhibiting
M2-like polarization of tumor associated macrophages. Oncotarget
6:36441–36455
Dutta A, Li J, Fedele C, Sayeed A, Singh A, Violette SM, Manes TD,
Languino LR (2015) Alphavbeta6 integrin is required for
TGFbeta1-mediated matrix metalloproteinase2 expression.
Biochem J 466:525–536
Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross
SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A,
Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST
(2013) A human monoclonal antibody 264RAD targeting
alphavbeta6 integrin reduces tumour growth and metastasis, and
modulates key biomarkers in vivo. Oncogene 32:4406–4416
Eberlein C, Rooney C, Ross SJ, Farren M, Weir HM, Barry ST (2015) E-
Cadherin and EpCAMexpression byNSCLC tumour cells associate
with normal fibroblast activation through a pathway initiated by
integrin αvβ6 and maintained through TGFβ signalling.Oncogene
34:704–716
Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ,
Wistuba II, Roth JA, McGuire MJ, Brown KC (2007) A pep-
tide selected by biopanning identifies the integrin alphavbeta6
as a prognostic biomarker for nonsmall cell lung cancer. Cancer
Res 67:5889–5895
Elez E, Kocakova I, Hohler T, Martens UM, Bokemeyer C, Van Cutsem
E, Melichar B, Smakal M, Csoszi T, Topuzov E, Orlova R,
Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J
(2015) Abituzumab combined with cetuximab plus irinotecan ver-
sus cetuximab plus irinotecan alone for patients with KRAS wild-
type metastatic colorectal cancer: the randomised phase I/II
POSEIDON trial. Ann Oncol 26:132–40
Fine JD, Hintner H (2009) Life with epidermolysis bullosa (EB): etiology,
diagnosis, multidisciplinary care and therapy. Springer, Vienna
Fontana L, Chen Y, Prijatelj P, Sakai T, Fassler R, Sakai LY, Rifkin DB
(2005) Fibronectin is required for integrin alphavbeta6-mediated
activation of latent TGF-beta complexes containing LTBP-1.
FASEB J 19:1798–1808
Cell Tissue Res (2016) 365:657–673 669
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS,
Albelda SM (2009) Polarization of tumor-associated neutrophil pheno-
type by TGF-beta: BN1^ versus BN2^ TAN. Cancer Cell 16:183–194
FriedlanderM, Brooks PC, Shaffer RW, Kincaid CM,Varner JA, Cheresh
DA (1995) Definition of two angiogenic pathways by distinct alpha
v integrins. Science 270:1500–1502
Friesenhengst A, Pribitzer-Winner T, Schreiber M (2014) Association of
the G473A polymorphism and expression of lysyl oxidase with
breast cancer risk and survival in European women: a hospital-
based case–control study. PLoS One 9:e105579
Fukuda K, Sugihara E, Ohta S, Izuhara K, Funakoshi T, Amagai M, Saya
H (2015) Periostin is a key niche component for wound metastasis
of melanoma. PLoS One 10:e0129704
Garnero P (2012) The contribution of collagen crosslinks to bone
strength. Bonekey Rep 1:182
Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E (2009)
Localized and reversible TGFbeta signalling switches breast cancer
cells from cohesive to single cell motility. Nat Cell Biol 11:1287–
1296
Gong D, Shi W, Yi SJ, Chen H, Groffen J, Heisterkamp N (2012)
TGFbeta signaling plays a critical role in promoting alternative mac-
rophage activation. BMC Immunol 13:31
Goodman SL, Holzemann G, Sulyok GA, Kessler H (2002) Nanomolar
small molecule inhibitors for alphav(beta)6, alphav(beta)5, and
alphav(beta)3 integrins. J Med Chem 45:1045–1051
Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten
Dijke P (2002) Balancing the activation state of the endothelium
via two distinct TGF-beta type I receptors. EMBO J 21:1743–1753
Grzeszkiewicz TM, Kirschling DJ, Chen N, Lau LF (2001) CYR61 stim-
ulates human skin fibroblast migration through integrin alpha vbeta
5 and enhances mitogenesis through integrin alpha vbeta 3, inde-
pendent of its carboxyl-terminal domain. J Biol Chem 276:21943–
21950
Guo L, Zhang Y, Zhang L, Huang F, Li J, Wang S (2016) MicroRNAs,
TGF-beta signaling, and the inflammatory microenvironment in
cancer. Tumour Biol 37:115–125
Gutheil JC, Campbell TN, Pierce PR,Watkins JD, HuseWD, Bodkin DJ,
Cheresh DA (2000) Targeted antiangiogenic therapy for cancer
using Vitaxin: a humanized monoclonal antibody to the integrin
alphavbeta3. Clin Cancer Res 6:3056–3061
Hagemann T,Wilson J, Burke F, KulbeH, Li NF, PluddemannA, Charles
K, Gordon S, Balkwill FR (2006) Ovarian cancer cells polarize
macrophages toward a tumor-associated phenotype. J Immunol
176:5023–5032
Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH,
Simon KJ, Chun Wang L, Leone DR, Lobb RR, McCrann DJ,
Allaire NE, Horan GS, Fogo A, Kalluri R, Shield CF 3rd,
Sheppard D,Gardner HA, Violette SM (2007) Alphav beta6 integrin
regulates renal fibrosis and inflammation in Alport mouse. Am J
Pathol 170:110–125
Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM,
Weinreb PH, Fleuren GJ (2007) Overexpression of the alpha v beta
6 integrin in cervical squamous cell carcinoma is a prognostic factor
for decreased survival. J Pathol 212:316–324
Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD,
McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski
PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert
A, Adams RH, Sheppard D (2013) Targeting of alphav integrin
identifies a core molecular pathway that regulates fibrosis in several
organs. Nat Med 19:1617–1624
Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R,
Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L,
Kirkwood JM (2010) A randomized phase 2 study of etaracizumab,
a monoclonal antibody against integrin alpha(v)beta(3), + or -
dacarbazine in patients with stage IV metastatic melanoma. Cancer
116:1526–1534
Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B,
O’Dell MR, Rivera LB, Harper J, Lonning S, Brekken RA,
Bardeesy N (2012) TGF-beta and alphavbeta6 integrin act in a com-
mon pathway to suppress pancreatic cancer progression. Cancer Res
72:4840–4845
Hou X,WuX, Huang P, Zhan J, Zhou T,MaY, Qin T, Luo R, Feng Y, Xu
Y, Chen L, Zhang L (2015) Osteopontin is a useful predictor of bone
metastasis and survival in patients with locally advanced nasopha-
ryngeal carcinoma. Int J Cancer 137:1672–1678
Hu H, Hang JJ, Han T, Zhuo M, Jiao F, Wang LW (2016) The M2
phenotype of tumor-associated macrophages in the stroma confers
a poor prognosis in pancreatic cancer. Tumour Biol. doi:10.1007
/s13277-015-4741-z
Hu X, Li N, Tao K, Fang X, Liu J, Wang Y, Wang H, Shi J, Wang Y, Ji P,
Cai W, Bai X, Zhu X, Han J, Hu D (2014) Effects of integrin ανβ3
on differentiation and collagen synthesis induced by connective tis-
sue growth factor in human hypertrophic scar fibroblasts. Int J Mol
Med 34:1323–1334
Huang XZ, Wu JF, Cass D, Erle DJ, Corry D, Young SG, Farese RV Jr,
Sheppard D (1996) Inactivation of the integrin beta 6 subunit gene
reveals a role of epithelial integrins in regulating inflammation in the
lung and skin. J Cell Biol 133:921–928
Huang X, Xiao DW, Xu LY, Zhong HJ, Liao LD, Xie ZF, Li EM (2009)
Prognostic significance of altered expression of SDC2 and CYR61
in esophageal squamous cell carcinoma. Oncol Rep 21:1123–1129
Hubbard R, Venn A, Lewis S, Britton J (2000) Lung cancer and crypto-
genic fibrosing alveolitis. A population-based cohort study. Am J
Respir Crit Care Med 161:5–8
Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC,
Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo
AM, Joyce JA, De Palma M, Pollard JW, Lewis CE (2015)
Perivascular M2 macrophages stimulate tumor relapse after chemo-
therapy. Cancer Res 75:3479–3491
Inman GJ (2011) Switching TGFbeta from a tumor suppressor to a tumor
promoter. Curr Opin Genet Dev 21:93–99
Jenkins G (2008) The role of proteases in transforming growth factor-beta
activation. Int J Biochem Cell Biol 40:1068–1078
Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, Chun GT, Kim NS, Yie
SW, Byeon WH, Eom SH, Ha KS, Kim YM, Kim PH (2007)
Mechanisms underlying TGF-beta1-induced expression of VEGF
and Flk-1 in mouse macrophages and their implications for angio-
genesis. J Leukoc Biol 81:557–566
Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, Krishnappa S,
Pinilla S, Droll L, Song YH (2010) Adipose tissue-derived stem
cells differentiate into carcinoma-associated fibroblast-like cells un-
der the influence of tumor-derived factors. Anal Cell Pathol (Amst)
33:61-79
Jun JI, Lau LF (2010) The matricellular protein CCN1 induces fibroblast
senescence and restricts fibrosis in cutaneous wound healing. Nat
Cell Biol 12:676–685
Kaartinen V, Voncken JW, Shuler C,Warburton D, BuD, HeisterkampN,
Groffen J (1995) Abnormal lung development and cleft palate in
mice lacking TGF-beta 3 indicates defects of epithelial-
mesenchymal interaction. Nat Genet 11:415–421
Kang JS, Liu C, Derynck R (2009) New regulatory mechanisms of TGF-
beta receptor function. Trends Cell Biol 19:385–394
Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M,
Kichenadasse G, Ackland S, Wheeler H (2016) Cilengitide with
metronomic temozolomide, procarbazine, and standard radiotherapy
in patients with glioblastoma and unmethylated MGMT gene pro-
moter in ExCentric, an open-label phase II trial. J Neuro-Oncol 128:
163–171
Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovacs N, Adany R,
Balazs M (2015) The role of osteopontin expression in melanoma
progression. Tumour Biol 36:7841–7847
670 Cell Tissue Res (2016) 365:657–673
Klingberg F, Chow ML, Koehler A, Boo S, Buscemi L, Quinn TM,
Costell M, Alman BA, Genot E, Hinz B (2014) Prestress in the
extracellular matrix sensitizes latent TGF-beta1 for activation. J
Cell Biol 207:283–297
Kothari AN, Arffa ML, Chang V, Blackwell RH, Syn WK, Zhang J, Mi
Z, Kuo PC (2016) Osteopontin-A master regulator of epithelial-
mesenchymal transition. J Clin Med 5:39
Kotobuki Y, Yang L, Serada S, Tanemura A, Yang F, Nomura S, Kudo A,
Izuhara K, Murota H, Fujimoto M, Katayama I, Naka T (2014)
Periostin accelerates human malignant melanoma progression by
modifying the melanoma microenvironment. Pigment Cell
Melanoma Res 27:630–639
Krstic J, Santibanez JF (2014) Transforming growth factor-beta and ma-
trix metalloproteinases: functional interactions in tumor stroma-
infiltrating myeloid cells. ScientificWorldJournal 2014:521754
Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC,
Roberts AB, Sporn MB, Ward JM, Karlsson S (1993)
Transforming growth factor beta 1 null mutation in mice causes
excessive inflammatory response and early death. Proc Natl Acad
Sci U S A 90:770–774
Landre V, Antonov A, Knight R, Melino G (2016) p73 promotes glio-
blastoma cell invasion by directly activating POSTN (periostin) ex-
pression. Oncotarget 7:11785–11802
Lau LF (2011) CCN1/CYR61: the very model of a modern matricellular
protein. Cell Mol Life Sci 68:3149–3163
Leask A (2013) Integrin 1: a mechanosignaling sensor essential for con-
nective tissue deposition by fibroblasts. Adv Wound Care 2:160–166
Lee YH, Albig AR, Regner M, Schiemann BJ, Schiemann WP (2008)
Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and en-
hances EMT induced by TGF-beta in mammary epithelial cells via a
MMP-dependent mechanism. Carcinogenesis 29:2243–2251
Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R
(2008)Osteopontin expression is required for myofibroblast
differentiation.Circ Res 102:319–327
Levy L, Hill CS (2005) Smad4 dependency defines two classes of
transforming growth factor {beta} (TGF-{beta}) target genes and
distinguishes TGF-{beta}-induced epithelial-mesenchymal transi-
tion from its antiproliferative and migratory responses. Mol Cell
Biol 25:8108–8125
Lewis MP, Lygoe KA, Nystrom ML, Anderson WP, Speight PM,
Marshall JF, Thomas GJ (2004) Tumour-derived TGF-beta1 modu-
lates myofibroblast differentiation and promotes HGF/SF-
dependent invasion of squamous carcinoma cells. Br J Cancer 90:
822–832
Li C, Guo B, Bernabeu C, Kumar S (2001) Angiogenesis in breast cancer:
the role of transforming growth factor beta and CD105.Microsc Res
Tech 52:437–449
Lin RL, Zhao LJ (2015) Mechanistic basis and clinical relevance of the
role of transforming growth factor-beta in cancer. Cancer Biol Med
12:385–393
LudlowA, Yee KO, LipmanR, Bronson R,Weinreb P, HuangX, Sheppard
D, Lawler J (2005) Characterization of integrin beta6 and
thrombospondin-1 double-null mice. J Cell Mol Med 9:421–437
Malik R, Lelkes PI, Cukierman E (2015) Biomechanical and biochemical
remodeling of stromal extracellular matrix in cancer. Trends
Biotechnol 33:230–236
Mamuya FA, Duncan MK (2012) aV integrins and TGF-beta-induced
EMT: a circle of regulation. J Cell Mol Med 16:445–455
Margadant C, Sonnenberg A (2010) Integrin-TGF-beta crosstalk in fibro-
sis, cancer and wound healing. EMBO Rep 11:97–105
Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ
(2008) Alpha vbeta 6 integrin promotes the invasion of morphoeic
basal cell carcinoma through stromal modulation. Cancer Res 68:
3295–3303
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile
T, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana JS,
Marshall JF, Hart IR, Hackshaw AK, Piper K, Thomas GJ (2011)
Stromal features are predictive of disease mortality in oral cancer
patients. J Pathol 223:470–481
Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF,
KimMH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kahari VM,
Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O’Toole EA
(2016) Suppression of TGFbeta and angiogenesis by type VII col-
lagen in cutaneous SCC. J Natl Cancer Inst 108:djv293
Maruhashi T, Kii I, SaitoM, Kudo A (2010) Interaction between periostin
and BMP-1 promotes proteolytic activation of lysyl oxidase. J Biol
Chem 285:13294–13303
McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ (2011) CD4+
CD25+ regulatory T cells control CD8+ T-cell effector differentia-
tion by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A
108:7529–7534
Medici D, Hay ED, Goodenough DA (2006) Cooperation between snail
and LEF-1 transcription factors is essential for TGF-beta1-induced
epithelial-mesenchymal transition. Mol Biol Cell 17:1871–1879
Miles FL, Sikes RA (2014) Insidious changes in stromal matrix fuel
cancer progression. Mol Cancer Res 12:297–312
Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E,
Timpson P, Leach J,McGarry L, Shanks E, Bailey P, Chang D, Oien
K, Karim S, Au A, Steele C, Carter CR, McKay C, Anderson K,
Evans TR, Marais R, Springer C, Biankin A, Erler JT, Sansom OJ
(2015) Targeting the LOX/hypoxia axis reverses many of the fea-
tures that make pancreatic cancer deadly: inhibition of LOX abro-
gates metastasis and enhances drug efficacy. EMBO Mol Med 7:
1063–1076
Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O (2006)
Organ-specific endoglin (CD105) expression in the angiogenesis of
human cancers. Pathol Int 56:717–723
Mohammed J, Beura LK, Bobr A, Astry B, Chicoine B, Kashem SW,
Welty NE, Igyarto BZ, Wijeyesinghe S, Thompson EA, Matte C,
Bartholin L, Kaplan A, Sheppard D, Bridges AG, Shlomchik WD,
Masopust D, Kaplan DH (2016) Stromal cells control the epithelial
residence of DCs and memory T cells by regulated activation of
TGF-beta. Nat Immunol 17:414–421
Moore KM, Thomas GJ, Duffy SW,Warwick J, Gabe R, Chou P, Ellis IO,
Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R,
Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan
L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry
ST, Hart IR, Jones JL, Marshall JF (2014) Therapeutic targeting of
integrin alphavbeta6 in breast cancer. J Natl Cancer Inst 106:dju169
Mori S, Kodaira M, Ito A, Okazaki M, Kawaguchi N, Hamada Y, Takada
Y, Matsuura N (2015) Enhanced expression of integrin alphavbeta3
induced by TGF-beta is required for the enhancing effect of fibro-
blast growth factor 1 (FGF1) in TGF-beta-induced epithelial-
mesenchymal transition (EMT) in mammary epithelial cells. PLoS
One 10:e0137486
Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G,
Glick A, Sheppard D (2003) Loss of integrin alpha(v)beta6-mediat-
ed TGF-beta activation causes Mmp12-dependent emphysema.
Nature 422:169–173
Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H,
Sheppard D, Broaddus VC, Nishimura SL (2002) The integrin
alpha(v)beta8 mediates epithelial homeostasis through MT1-
MMP-dependent activation of TGF-beta1. J Cell Biol 157:493–507
Munger JS, HuangX, Kawakatsu H, GriffithsMJ, Dalton SL,Wu J, Pittet
JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D
(1999) The integrin alpha v beta 6 binds and activates latent TGF
beta 1: a mechanism for regulating pulmonary inflammation and
fibrosis. Cell 96:319–328
Naber HP, Drabsch Y, Snaar-Jagalska BE, ten Dijke P, van Laar T (2013)
Snail and Slug, key regulators of TGF-beta-induced EMT, are suf-
ficient for the induction of single-cell invasion. Biochem Biophys
Res Commun 435:58–63
Cell Tissue Res (2016) 365:657–673 671
Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, sub-
version and escape: the role of regulatory T cells in cancer progres-
sion. Clin Exp Immunol 171:36–45
Orlova VV, Liu Z, Goumans MJ, ten Dijke P (2011) Controlling angio-
genesis by two unique TGF-beta type I receptor signaling pathways.
Histol Histopathol 26:1219–1230
Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC,
Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De
Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses
HL,Weaver VM,Maitra A, Allison JP, LeBleuVS, Kalluri R (2014)
Depletion of carcinoma-associated fibroblasts and fibrosis induces
immunosuppression and accelerates pancreas cancer with reduced
survival. Cancer Cell 25:719–734
Pedroja BS, Kang LE, Imas AO, Carmeliet P, Bernstein AM (2009)
Plasminogen activator inhibitor-1 regulates integrin alphavbeta3 ex-
pression and autocrine transforming growth factor beta signaling. J
Biol Chem 284:20708–20717
Petrillo M, Zannoni GF, Martinelli E, Pedone Anchora L, Ferrandina G,
Tropeano G, Fagotti A, Scambia G (2015) Polarisation of tumor-
associated macrophages toward M2 phenotype correlates with poor
response to chemoradiation and reduced survival in patients with
locally advanced cervical cancer. PLoS One 10:e0136654
Pickup M, Novitskiy S, Moses HL (2013) The roles of TGFbeta in the
tumour microenvironment. Nat Rev Cancer 13:788–799
Platzer G, Schedlbauer A, Chemelli A, Ozdowy P, Coudevylle N, Auer R,
Kontaxis G, Hartl M, Miles AJ, Wallace BA, Glatter O, Bister K,
Konrat R (2011) The metastasis-associated extracellular matrix pro-
tein osteopontin forms transient structure in ligand interaction sites.
Biochemistry 50:6113–6124
Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W,
LoBuglio AF (2001) A pilot trial of Vitaxin, a humanized anti-
vitronectin receptor (anti alpha v beta 3) antibody in patients with
metastatic cancer. Cancer Biother Radiopharm 16:125–132
Principe DR, DeCant B, Mascarinas E, Wayne E, Diaz A, Akagi N,
Hwang RF, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi
HG, Jung B, Grippo PJ (2016) TGFbeta signaling in the pancreatic
tumor microenvironment promotes fibrosis and immune evasion to
facilitate tumorigenesis. Cancer Res (in press)
Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely
PJ (2006) Collagen reorganization at the tumor-stromal interface
facilitates local invasion. BMC Med 4:38
Qin X, Yan M, Zhang J, Wang X, Shen Z, Lv Z, Li Z, Wei W, Chen W
(2016) TGFbeta3-mediated induction of Periostin facilitates head
and neck cancer growth and is associated with metastasis. Sci Rep
6:20587
Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD,
Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT,
Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker
GC, Hodivala-Dilke KM (2009) Stimulation of tumor growth and
angiogenesis by low concentrations of RGD-mimetic integrin inhib-
itors. Nat Med 15:392–400
Reynolds LE, Conti FJ, Lucas M, Grose R, Robinson S, Stone M,
Saunders G, Dickson C, Hynes RO, Lacy-Hulbert A, Hodivala-
Dilke K (2005) Accelerated re-epithelialization in beta3-integrin-
deficient-mice is associated with enhanced TGF-beta1 signaling.
Nat Med 11:167–174
Rhim AD, Oberstein PE, Thomas DH,Mirek ET, Palermo CF, Sastra SA,
Dekleva EN, Saunders T, Becerra CP, Tattersall IW,Westphalen CB,
Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME,
Iacobuzio-Donahue C, Olive KP, Stanger BZ (2014) Stromal ele-
ments act to restrain, rather than support, pancreatic ductal adeno-
carcinoma. Cancer Cell 25:735–747
Roberts AB,Wakefield LM (2003) The two faces of transforming growth
factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100:8621–
8623
Robertson IB, Horiguchi M, Zilberberg L, Dabovic B, Hadjiolova K,
Rifkin DB (2015) Latent TGF-beta-binding proteins. Matrix Biol
47:44–53
Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B (2003)
Activated integrin alphavbeta3 cooperates with metalloproteinase
MMP-9 in regulating migration of metastatic breast cancer cells.
Proc Natl Acad Sci U S A 100:9482–9487
Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF (2004)
Endoglin (CD105) and vascular endothelial growth factor as prognos-
tic markers in colorectal cancer. Modern Pathol 17:197–203
Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, Damti P,
Lumbroso D, Polyansky L, Sionov RV, Ariel A, Hovav AH, Henke
E, Fridlender ZG, Granot Z (2015) Phenotypic diversity and plas-
ticity in circulating neutrophil subpopulations in cancer. Cell Rep
10:562–573
Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, FriedmanR,
Boivin GP, Cardell EL, Doetschman T (1997) TGFbeta2 knockout
mice have multiple developmental defects that are non-overlapping
with other TGFbeta knockout phenotypes. Development 124:2659–
2670
Schmidt A, Zhang XM, Joshi RN, Iqbal S, Wahlund C, Gabrielsson S,
Harris RA, Tegner J (2016) Humanmacrophages induce CD4Foxp3
regulatory T cells via binding and re-release of TGF-beta. Immunol
Cell Biol (in press)
Shang B, Liu Y, Jiang SJ (2015) Prognostic value of tumor-infiltrating
FoxP3+ regulatory T cells in cancers: a systematic review and meta-
analysis. Sci Rep 5:15179
Sheppard D (2015) Epithelial-mesenchymal interactions in fibrosis and
repair. Transforming growth factor-beta activation by epithelial cells
and fibroblasts. Ann Am Thorac Soc 12 (Suppl 1):S21–S23
ShermanMH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson
EA, Connor F, VanDyke T, Kozlov S,Martin P, Tseng TW, Dawson
DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV,
Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T,
Drebin JA, O’Dwyer PJ, Liddle C, Tuveson DA, Downes M,
Evans RM (2014) Vitamin D receptor-mediated stromal
reprogramming suppresses pancreatitis and enhances pancreatic
cancer therapy. Cell 159:80–93
Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen
R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T
(1992) Targeted disruption of themouse transforming growth factor-
beta 1 gene results in multifocal inflammatory disease. Nature 359:
693–699
Silva R, D’AmicoG, Hodivala-Dilke KM,Reynolds LE (2008) Integrins:
the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol
28:1703–1713
Sionov RV, Fridlender ZG, Granot Z (2015) The multifaceted roles neu-
trophils play in the tumor microenvironment. Cancer Microenviron
8:125–158
Sipos B, HahnD, Carceller A, Piulats J, Hedderich J, Kalthoff H, Goodman
SL, Kosmahl M, Kloppel G (2004) Immunohistochemical screening
for beta6-integrin subunit expression in adenocarcinomas using a nov-
el monoclonal antibody reveals strong up-regulation in pancreatic
ductal adenocarcinomas in vivo and in vitro. Histopathology 45:
226–236
Slack RJ, Hafeji M, Rogers R, Ludbrook SB, Marshall JF, Flint DJ, Pyne
S, Denyer JC (2016) Pharmacological characterization of the
alphavbeta6 integrin binding and internalization kinetics of the
foot-and-mouth disease virus derived peptide A20FMDV2.
Pharmacology 97:114–125
Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D (2008) Involvement of
Cyr61 in growth, migration, and metastasis of prostate cancer cells.
Br J Cancer 99:1656–1667
Sung PL, Jan YH, Lin SC, Huang CC, Lin H, Wen KC, Chao KC, Lai
CR, Wang PH, Chuang CM, Wu HH, Twu NF, Yen MS, Hsiao M,
Huang CY (2016) Periostin in tumor microenvironment is
672 Cell Tissue Res (2016) 365:657–673
associated with poor prognosis and platinum resistance in epithelial
ovarian carcinoma. Oncotarget 7:4036–4047
Tchaicha JH, Mobley AK, HossainMG, Aldape KD,McCarty JH (2010)
A mosaic mouse model of astrocytoma identifies alphavbeta8
integrin as a negative regulator of tumor angiogenesis. Oncogene
29:4460–4472
Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, McCarty JH
(2011) Glioblastoma angiogenesis and tumor cell invasiveness are
differentially regulated by beta8 integrin. Cancer Res 71:6371–6381
Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC (2012) Endoglin
mediates fibronectin/alpha5beta1 integrin and TGF-beta pathway
crosstalk in endothelial cells. EMBO J 31:3885–3900
Travis MA, Sheppard D (2014) TGF-beta activation and function in im-
munity. Annu Rev Immunol 32:51–82
TravisMA, Reizis B,Melton AC,Masteller E, TangQ, Proctor JM,Wang
Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D
(2007) Loss of integrin alpha(v)beta8 on dendritic cells causes au-
toimmunity and colitis in mice. Nature 449:361–365
Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le Devedec SE,
Balcioglu HE, He S, Snaar-Jagalska BE, Vreugdenhil E, Meerman
JH, van de Water B, Danen EH (2014) Beta1 integrin inhibition
elicits a prometastatic switch through the TGFbeta-miR-200-ZEB
network in E-cadherin-positive triple-negative breast cancer. Sci
Signal 7:ra15
Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ,
Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C,
Primrose JN, Blaydes JP, Thomas GJ (2015) Cancer-associated fi-
broblasts predict poor outcome and promote periostin-dependent
invasion in oesophageal adenocarcinoma. J Pathol 235:466–477
Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage
DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS,
Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb
PH, Fawell SE, Violette SM (2008) Antibody-mediated blockade of
integrin alpha v beta 6 inhibits tumor progression in vivo by a
transforming growth factor-beta-regulated mechanism. Cancer Res
68:561–570
Vinals F, Pouyssegur J (2001) Transforming growth factor beta1 (TGF-
beta1) promotes endothelial cell survival during in vitro angiogene-
sis via an autocrine mechanism implicating TGF-alpha signaling.
Mol Cell Biol 21:7218–7230
Wakefield LM, Hill CS (2013) Beyond TGFbeta: roles of other TGFbeta
superfamily members in cancer. Nat Rev Cancer 13:328–341
Weber CE, Kothari AN,Wai PY, Li NY, Driver J, Zapf MA, Franzen CA,
Gupta GN, Osipo C, Zlobin A, Syn WK, Zhang J, Kuo PC, Mi Z
(2015) Osteopontin mediates anMZF1-TGF-beta1-dependent trans-
formation of mesenchymal stem cells into cancer-associated fibro-
blasts in breast cancer. Oncogene 34:4821–4833
Weis SM, Cheresh DA (2011) AlphaV integrins in angiogenesis and
cancer. Cold Spring Harbor Perspect Med 1:a006478
Wipff PJ, Hinz B (2008) Integrins and the activation of latent
transforming growth factor beta1—an intimate relationship. Eur J
Cell Biol 87:601–615
Wipff PJ, Rifkin DB, Meister JJ, Hinz B (2007) Myofibroblast contrac-
tion activates latent TGF-beta1 from the extracellular matrix. J Cell
Biol 179:1311–1323
Wong PP, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MR,
Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S,
Elia G, Hagemann T, Kocher HM, Hodivala-Dilke KM (2015)
Dual-action combination therapy enhances angiogenesis while re-
ducing tumor growth and spread. Cancer Cell 27:123–137
Wu Q, Chen GL, Li YJ, Chen Y, Lin FZ (2015) Paeoniflorin inhibits
macrophage-mediated lung cancer metastasis. Chin J Nat Med 13:
925–932
XuX, ChangW, Yuan J, Han X, TanX, DingY, LuoY, Cai H, LiuY, Gao
X, Liu Q, YuY, DuY,WangH,Ma L,Wang J, ChenK, FuC, Cao G
(2016) Periostin expression in intra-tumoral stromal cells is prog-
nostic and predictive for colorectal carcinoma via creating a cancer-
supportive niche. Oncotarget 7:798–813
Xu YY, Zhang YY, Lu WF, Mi YJ, Chen YQ (2015) Prognostic value of
osteopontin expression in breast cancer: a meta-analysis. Mol Clin
Oncol 3:357–362
Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama
K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A,
Harada S, Yamamoto H, Ohta T (2015) Tumor-associated macro-
phages of the M2 phenotype contribute to progression in gastric
cancer with peritoneal dissemination. Gastric Cancer (in press)
Yanagisawa H, Schluterman MK, Brekken RA (2009) Fibulin-5, an
integrin-binding matricellular protein: its function in development
and disease. J Cell Commun Signal 3:337–347
Yang L, Moses HL (2008) Transforming growth factor beta: tumor sup-
pressor or promoter? Are host immune cells the answer? Cancer Res
68:9107–9111
Yang M, Liu J, Piao C, Shao J, Du J (2015) ICAM-1 suppresses tumor
metastasis by inhibiting macrophage M2 polarization through
blockade of efferocytosis. Cell Death Dis 6:e1780
Yang Z,MuZ, Dabovic B, Jurukovski V, YuD, Sung J, Xiong X,Munger
JS (2007) Absence of integrin-mediated TGFbeta1 activation
in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell
Biol 176:787–793
Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, Reichardt LF (2002)
Beta8 integrins are required for vascular morphogenesis in mouse
embryos. Development 129:2891–2903
Zhu J, Huang S,Wu G, Huang C, Li X, Chen Z, Zhao L, Zhao Y (2015a)
Lysyl oxidase is predictive of unfavorable outcomes and essential
for regulation of vascular endothelial growth factor in hepatocellular
carcinoma. Dig Dis Sci 60:3019–3031
ZhuX, Zhong J, Zhao Z, Sheng J,Wang J, Liu J, Cui K, Chang J, Zhao H,
Wong S (2015b) Epithelial derived CTGF promotes breast tumor
progression via inducing EMT and collagen I fibers deposition.
Oncotarget 6:25320–25338
Cell Tissue Res (2016) 365:657–673 673
